analytics / biologic
Analytical Basics for Biologics
April Stanley, MS MBA
Nice Insight
NI-8-26-MA37Sep 15, 2026
mRNA analytics
The mRNA Therapeutics Analytical Landscape
David Alvaro, Ph.D.; April Stanley, MS MBA
Pharma's Almanac
NI-8-26-MA10Sep 15, 2026
Development CDMO
The Case for Earlier CDMO Involvement in Drug Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-09-26-PA-02Sep 2, 2026
mRNA / analytical
The mRNA Therapeutics Analytical Landscape
David Alvaro, Ph.D.; April Stanley, MS MBA
Pharma's Almanac
NI-8-26-MA3Aug 28, 2026
cell therapy
Core Analytical Frameworks in Cell Therapy Quality Control
April Stanley, MS MBA
Nice Insight
NI-8-26-MA38Aug 28, 2026
mRNA / Analytics
Analytical Landscape of Viral Vectors
April Stanley, MS MBA
Nice Insight
NI-8-26-MA44Aug 27, 2026
Potency Assurance
Why Potency Cannot Be Reduced to a Release Assay in Active Immunotherapy Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-16Aug 24, 2026
Oligo Analytics
Impurities, Sequence Fidelity, and Structural Variants in Nucleic Acid Therapeutics
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-23May 26, 2026
Pathfinder
In Vitro vs. In Vivo Potency Assays: Which Approach Is Best for Biopharmaceutical Product Characterization?
Nice Insight
PAO-26-PF-07May 15, 2026